Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunogen Inc
(NQ:
IMGN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunogen Inc
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH
December 10, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
December 09, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Via
Benzinga
Looking Into Immunogen's Return On Capital Employed
November 28, 2022
Via
Benzinga
After FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This Analyst
November 16, 2022
Via
Benzinga
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
December 01, 2022
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Expert Ratings for Immunogen
November 16, 2022
Via
Benzinga
Why Jim Cramer Sees 'Another Bad Quarter Ahead' For Ford, And What Will Turn Things Around
November 23, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vista Outdoor Inc (NYSE: VSTO) can be "bought here. I would not push it, though."
Via
Benzinga
ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer
November 21, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Vodafone, Getty Images Holdings, Haynes International And Some Other Big Stocks Moving Lower On Tuesday
November 15, 2022
U.S. stocks traded higher, with the Nasdaq gaining more than 200 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
PDS Biotechnology To Rally Around 129%? Here Are 5 Other Price Target Changes For Tuesday
November 15, 2022
Via
Benzinga
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
November 16, 2022
Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday.
Via
Benzinga
HUYA, Tencent Music Entertainment, Taiwan Semiconductor Manufacturing, And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
November 15, 2022
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer
November 15, 2022
Via
Benzinga
ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
November 14, 2022
From
ImmunoGen Inc.
Via
Business Wire
Recap: Immunogen Q3 Earnings
November 04, 2022
Immunogen (NASDAQ:IMGN) reported its Q3 earnings results on Friday, November 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Immunogen missed estimated earnings...
Via
Benzinga
ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results
November 04, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Preview: Immunogen's Earnings
November 03, 2022
Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-11-04. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will...
Via
Benzinga
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Earnings Scheduled For November 4, 2022
November 04, 2022
Companies Reporting Before The Bell • Sprott (NYSE:SII) is likely to report quarterly earnings at $0.49 per share on revenue of $49.95 million. • Telefonica (NYSE:TEF) is likely to report earnings for...
Via
Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
ImmunoGen Announces Departure of Chief Commercial Officer
November 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO
October 28, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results
October 20, 2022
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS
September 29, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference
September 14, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
September 11, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Upgrades
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.